Addex Therapeutics Ltd.
ADXN · XNASCIK 1574232fmd_0D5SN8Z9P3H4Y5X1M4Q7GHNN7RManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2017 to Dec 31, 2025, 19 periods
| Line item | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|---|---|---|
| Total revenues | – | 6 | 3 | 4 | 3 | 1 | 2 | 0 |
| Research and development | 3 | 5 | 12 | 10 | 13 | 8 | 1 | 1 |
| Operating income | (3) | (1) | (15) | (12) | (16) | (11) | (2) | (3) |
| Interest expense | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Income before taxes | (3) | (2) | (15) | (13) | (15) | (11) | (3) | (5) |
| Income tax expense | – | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | – | (2) | (15) | (13) | (15) | (11) | (3) | (5) |
| Net income | (3) | (2) | (15) | (13) | (15) | (21) | (11) | 7 |
| Net income to common shareholders | (3) | (2) | (15) | (13) | (15) | (21) | (11) | 7 |